At Treadwell Therapeutics, we are a clinical stage, multi-modality oncology company breaking away from the incremental mold. By pursuing novel targets for therapeutic intervention and housing our complete drug discovery and development engine under one roof, we aspire to overcome some of the biggest challenges in oncology today. This is the Treadwell Path to Better.
Forging New Ground
in novel biology to address the most pressing needs in cancer.
Multiple modalities, multiple assets.
Our team is rapidly advancing a science-driven, first-in-class pipeline against multiple novel targets for indications with limited treatment options. We are exploring various modalities while developing our clinical assets, including our small molecule, biologics and T-cell receptor-based cell therapy programs.
Concept to clinic – and beyond.
With a robust set of comprehensive internal discovery tools and capabilities, we translate innovative scientific ideas and therapeutic targets into practice-changing medicines. Our in-house drug discovery and development engine continues to generate promising targets and therapies, even as we advance our clinical candidates.